Clinical Trials Browser

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01587352 2026-04-13

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Active not recruiting

40 enrolled

Dermatologic

Uveal Melanoma

NCT01502085 2026-04-03

RZD

Phase 1/2 Completed

25 enrolled 5 charts

Plasma cell

Multiple Myeloma

NCT01522976 2026-03-31

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2 Active not recruiting

282 enrolled 11 charts

Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01297764 2026-03-23

QUAD

Phase 1/2 Active not recruiting

17 enrolled

Plasma cell

Multiple Myeloma

Clinical Trials

NYMC195

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

RZD

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

QUAD